FDA Mechanisms of SARS-CoV-2 Cellular Entry Internship
*Applications will be reviewed on a rolling basis.
A research opportunity is available in the Office of Pharmaceutical Quality/Office of Biotechnology Products (OBP), Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA) located in Silver Spring, Maryland. CDER performs an essential public health task by making sure that safe and effective drugs are available to improve the health of people in the United States. As part of the FDA, CDER regulates over-the-counter and prescription drugs, including biological therapeutics and generic drugs. This work covers more than just medicines.
This project explores the mechanisms of SARS-CoV-2 spike protein-mediated cell fusion using engineered non-infectious virus-like particles (VLP), focusing on the effect of different cytokines in human lung-derived epithelial cell lines, primary human lung epithelial cells, and/or human macrophages. A variety of similarly generated VLP, pseudotyped with alternative virus envelope glycoproteins will be studied as well. The project will also investigate VLP-induced cytokine secretion in various cell types and evaluate potential virus entry inhibitors.
Under the guidance of the mentor, the participant will learn laboratory and research techniques utilizing a variety of methods such as PCR, DNA purification, electrophoresis, Western blot analysis, flow cytometry, fluorescent microscopy, cell culture, etc. In addition, the participant will gain understanding of the mechanisms of virus entry.
This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The initial appointment is for one year, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time at FDA in the Silver Spring, Maryland, area. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.
If you have questions, send an email to ORISE.FDA.CDER@orau.org. Please include the reference code for this opportunity in your email.